Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2016

View Archived Issues

Award supports Catabasis Pharmaceuticals' evaluation of CAT-4001 for Friedreich's ataxia

sFlt-1:PlGF ratio could be used to predict pre-eclampsia in the short term

ImmunID to apply its ImmunTraCkeR assay to phase II trial of IRX-2 in HNSCC

Immunovia to conduct validation trial of IMMrayPanCan-d blood test

Stellar Biotechnologies and Neovacs to form joint venture

EMA grants orphan drug status for entolimod as a radiation countermeasure

Summit Therapeutics cleared to initiate phase II clinical trial of SMT-C1100

Bispecific antibodies neutralize both Zaire and Sudan Ebola virus strains

Vasopharm raises funds to progress treatment for traumatic brain injury

ST Pharm patents TANK1 inhibitors

Celgene discloses antiproliferative compounds

Janssen Pharmaceutica describes FFAR1 agonists

Ajinomoto divulges GS activators

Hetero Research Foundation presents antiviral agents

FDA awards orphan drug designation to Kevetrin for pancreatic cancer

ALKS-5461 fails to achieve primary endpoints in two phase III trials in MDD

Real-time fluorescence tracking helps targeting cancer therapy

Amgen's Repatha approved in Japan

Spark Therapeutics presents pipeline highlights

Dynavax and AstraZeneca amend AZD-1419 agreement

New FDA approvals for Kyprolis in relapsed or refractory multiple myeloma

Oncoceutics starts phase II trial of ONC-201 in glioblastoma multiforme

Scripps Research Institute develops new methods for building, altering drug molecules

MD Anderson and AbbVie form cancer immunotherapy collaboration

UCB's Briviact approved in E.U. as adjunctive treatment for partial-onset seizures

Gavi and Merck & Co. sign agreement in support of Ebola Zaire vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...